Ask about this productRelated genes to: MDM2 antibody
- Gene:
- MDM2 NIH gene
- Name:
- MDM2 proto-oncogene
- Previous symbol:
- -
- Synonyms:
- HDM2, MGC5370
- Chromosome:
- 12q15
- Locus Type:
- gene with protein product
- Date approved:
- 1993-12-10
- Date modifiied:
- 2017-12-01
Related products to: MDM2 antibody
Related articles to: MDM2 antibody
- Aneurysmal bone cysts (ABCs) of the skull are rare, particularly those arising in the occipital bone. Intracranial extension or dural destruction is extremely uncommon. Here, we report an occipital ABC-like lesion that recurred 19 months after gross-total resection with dural defects, intradural extension, and molecular evidence supporting aggressive neoplastic evolution. - Source: PubMed
Publication date: 2026/04/20
Shi XiaomanHuang XinyuejiaDeng HaoXiong YuWang WeiZhang Si - Pharmacologic targeting of murine double minute 2 (MDM2) represents one of the most compelling strategies for therapeutic reactivation of wild-type p53 in hematologic malignancies. The MDM2-p53 autoregulatory loop is a central regulator of cellular stress responses, and in myeloid neoplasms-including acute myeloid leukemia (AML) and myeloproliferative neoplasms (MPN)-p53 is frequently retained but functionally suppressed through MDM2 overexpression and oncogenic signaling, notably via JAK-STAT activation. Over the past decade, successive generations of MDM2 inhibitors have translated structural and mechanistic insights into clinical investigation, yielding critical lessons regarding dosing paradigms, hematologic toxicity, biomarker-driven patient selection, and mechanisms of resistance, including TP53-mutant clonal selection. While early phase III trials in AML were negative, recent studies in myelofibrosis demonstrate clinically meaningful spleen, symptom, and molecular responses, supporting disease-modifying potential in TP53-wild-type settings. Adaptive platform designs and rational combinations with JAK inhibitors, BCL-2 antagonists, and interferons have further refined therapeutic strategies. Emerging MDM2 degraders and next-generation agents aim to overcome feedback limitations and improve therapeutic index. This review integrates mechanistic foundations, clinical development, resistance biology, and future directions, highlighting how decades of basic science have reshaped p53 reactivation into a precision therapeutic paradigm in myeloid disease. - Source: PubMed
Publication date: 2026/05/05
Al-Ali Haifa KHeidel Sarah TPalandri FrancescaHeidel Florian H - Primary tumors of the pulmonary artery are rare and often mimic thromboembolic disease, leading to delayed diagnosis with potentially serious consequences. - Source: PubMed
Publication date: 2026/05/05
Matthias ChristophWiedemann ChristianeWaldsperger HannaKommoss Felix K FSchlegel PhilippEden MatthiasGeis NicolasAndré FlorianAbu Sharar HaithamLehmann LorenzFrey NorbertKonstandin MathiasMeder BenjaminSalatzki Janek - Adenomatoid tumor is a rare benign neoplasm of mesothelial origin occurring in various anatomical locations, including the uterus. In this article, we describe an adenomatoid tumor of the uterus exhibiting severe nuclear atypia in the clinical context of long-term hormone therapy. The patient was a 51-year-old woman who underwent total abdominal hysterectomy with bilateral salpingo-oophorectomy for uterine leiomyomas. Gross evaluation of the uterus revealed multiple intramural and subserosal unencapsulated nodules that were both well and poorly circumscribed and measured from 4 to 25 mm. Microscopically, one of the nodules consisted of hyperplastic leiomyocytes intermixed with irregular vascular-like and tubular spaces lined by flattened cells that occasionally showed moderate to severe nuclear atypia (enlargement, hyperchromasia, and multinucleation). Bizarre pleomorphic cells were also present. Mitotic activity was minimal. The tumor cells showed diffuse positivity for calretinin, keratin AE1/AE3, L1 cell adhesion molecule, and podoplanin, while CD31, CD34, epithelial membrane antigen, HMB45, MDM2, and S100 protein stains were negative. Expression of BRCA1-associated deubiquitinase 1 and methylthioadenosine phosphorylase was retained. This immunophenotype supported a mesothelial origin of the neoplastic cells, leading to the final diagnosis of adenomatoid tumor with marked nuclear atypia. Unusual histopathological findings in adenomatoid tumors, such as marked nuclear atypia and pleomorphism, may pose significant diagnostic challenges and result in misdiagnosis. Despite these unusual features, the tumor in our study showed no evidence of aggressive behavior or malignant transformation. Although we hypothesize that these changes may be related to prolonged hormone therapy, their pathogenesis and clinical significance remain unclear, underscoring the need for further investigation. - Source: PubMed
Publication date: 2026/05/05
Lenz JiříMichalová KvětoslavaPtáková NikolaKavka MiroslavSlonková VeronikaČerná JanaFiala Luděk - Retroperitoneal sarcoma (RPS) is a type of malignant tumour arising from mesenchymal tissues within the retroperitoneal space. RPSs tend to develop covertly and are often undiscovered when they have already grown significantly and invaded surrounding tissues and organs. These malignancies demonstrate high recurrence rates, present surgical challenges and exhibit limited responsiveness to radiotherapy and chemotherapy. Serum-derived molecules are known to play critical roles in tumourigenesis and tumour progression. However, the serum molecular profile of RPS patients remains unclear. - Source: PubMed
Xie Fu'anGu LingweiYang KunrongWang ShuaiXiao MengmengYan GuangtingZhang QuanLiang RubingZhuang AoboXi ZheNiu YujiaChen YanhuaXia XiaogangQu LinlinZhao BinLi WeibingWu TingYu ChundongLuo ChenghuaWang HouzhaoLian LanlanLi Wengang